- CT-388 achieved 22.5% placebo-adjusted weight loss at 48 weeks.
- 54% of participants on 24 mg dose resolved obesity vs. 13% placebo.
- Phase III trials for CT-388 in obesity start this quarter.
- CT-388 is also being tested for type 2 diabetes.
Study Results
Genentech's Phase II trial of CT-388, a dual GLP-1/GIP receptor agonist, showed significant weight loss in participants with obesity. A once-weekly 24 mg dose led to a 22.5% placebo-adjusted weight loss at 48 weeks, without reaching a plateau.
Participant Outcomes
54% of those on the 24 mg dose achieved obesity resolution (BMI <30 kg/m2) compared to 13% in the placebo group. Additionally, 73% of pre-diabetic participants on the 24 mg dose reached normal blood glucose levels, versus 7.5% in the placebo group.
Safety and Tolerability
CT-388 was well-tolerated, with most gastrointestinal-related adverse events being mild-to-moderate. The treatment discontinuation rate due to adverse events was low, at 5.9% for CT-388 and 1.3% for placebo.
Future Developments
CT-388 is advancing to Phase III trials for obesity, expected to start this quarter. It is also being investigated in another Phase II study for efficacy in participants with obesity or overweight and type 2 diabetes.
